SCHEMBL24256352

SCHEMBL24256352

CCCc1nc2sc3c(NCCc4ccc(Cl)c(Cl)c4)ncnc3c2c2c1CCC2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.51
RXFP1 Q9HBX9 2/20 0.51
OPRK1 P41145 2/20 0.51
KDM4E B2RXH2 6/20 0.48
RAD52 P43351 3/20 0.48
HTT P42858 3/20 0.48
MAPT P10636 2/20 0.48
MAPK1 P28482 2/20 0.48
IDE P14735 1/20 0.48
UBE2N P61088 1/20 0.48
KMT2A Q03164 2/20 0.47
ALDH1A1 P00352 5/20 0.46
LMNA P02545 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
HPGD P15428 2/20 0.46
ADRB2 P07550 1/20 0.46
GAA P10253 1/20 0.46
TSHR P16473 2/20 0.44
APOBEC3A P31941 1/20 0.44
RECQL P46063 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24256354 0.92 POLB (0.52) POLBRXFP1OPRK1KDM4ERAD52
SCHEMBL24256613 0.88 RAD52 (0.47) POLBRXFP1OPRK1KDM4ERAD52
SCHEMBL24256356 0.86 NPC1 (0.48) POLBRXFP1OPRK1KDM4ERAD52
SCHEMBL24256706 0.85 NPC1 (0.49) POLBRXFP1OPRK1KDM4ERAD52
SCHEMBL24256695 0.85 KDM4E (0.53) POLBRXFP1OPRK1KDM4ERAD52
SCHEMBL24256699 0.85 KDM4E (0.49) POLBRXFP1OPRK1KDM4ERAD52
SCHEMBL24256693 0.84 KDM4E (0.46) POLBRXFP1OPRK1KDM4ERAD52
SCHEMBL24256615 0.82 KDM4E (0.44) POLBRXFP1OPRK1KDM4ERAD52
SCHEMBL24256969 0.82 KDM4E (0.46) POLBRXFP1OPRK1KDM4ERAD52
SCHEMBL24256614 0.81 HTT (0.55) POLBRXFP1OPRK1KDM4ERAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
WO-2022035806-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP8 POLB 2123/4885RXFP1 4473/4885OPRK1 4624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.